Hôpital Côte de Nacre, Service d'Hépato-Gastroentérologie, Nutrition et Oncologie Digestive, Caen, France; UFR Santé Caen France: U1086 INSERM- "ANTICIPE", Caen, France.
Réseau Régional de Cancérologie OncoBasseNormandie, Caen, France.
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101514. doi: 10.1016/j.clinre.2020.07.019. Epub 2021 Mar 11.
After liver transplantation (LT),de novo malignancies are one of the leading causes of late mortality. The aim of the present retrospective study was to identify the risk factors of de novo malignancies in a large cohort of LT recipients in France, using Fine and Gray competing risks regression analysis.
The study population consisted in 11004 adults transplanted between 2000 and 2013, who had no history of pre-transplant malignancy, except primary liver tumor. A Cox model adapted to the identification of prognostic factors (competitive risks) was used.
From the entire cohort, one (or more)de novo malignancy was reported in 1480 L T recipients (13.45%). The probability to develop a de novo malignancy after LT was 2.07% at 1 year, 13.30% at 5 years, and 28.01% at 10 years. Of the known reported malignancies, the most common malignancies were hematological malignancy (22.36%), non-melanoma skin cancer (19.53%) and lung cancer (12.36%). According to Fine and Gray competing risks regression multivariate analysis, were significant risk factors for post-LT de novo malignancy: recipient age (Subdistribution Hazard Ratio (SHR) = 1.03 95%CI 1.03-1.04), male gender (SHR = 1.45 95%CI 1.27-1.67), non-living donor (SHR = 1.67 95%CI 1.14-2.38), a first LT (SHR = 1.35 95%CI 1.09-1.69) and the type of initial liver disease (alcohol-related liver disease (SHR = 1.63 95%CI 1.22-2.17), primary sclerosing cholangitis (SHR = 1.98 95%CI 1.34-2.91), and primary liver tumor (SHR = 1.88 95%CI 1.41-2.54)). Initial immunosuppressive regimen had no significant impact.
The present study confirms that LT recipient characteristics are associated with the risk ofde novo malignancy and this underlines the need for personalized screening in order to improve survival.
肝移植(LT)后,新发恶性肿瘤是导致晚期死亡的主要原因之一。本回顾性研究的目的是使用 Fine 和 Gray 竞争风险回归分析,在法国的大型 LT 受者队列中确定新发恶性肿瘤的风险因素。
研究人群包括 2000 年至 2013 年间接受移植的 11004 名成年人,除原发性肝肿瘤外,他们均无移植前恶性肿瘤史。使用适应于识别预后因素(竞争风险)的 Cox 模型。
在整个队列中,1480 名 LT 受者(13.45%)报告了 1 种(或多种)新发恶性肿瘤。LT 后新发恶性肿瘤的概率在 1 年内为 2.07%,5 年内为 13.30%,10 年内为 28.01%。在已知的报告恶性肿瘤中,最常见的恶性肿瘤是血液系统恶性肿瘤(22.36%)、非黑色素瘤皮肤癌(19.53%)和肺癌(12.36%)。根据 Fine 和 Gray 竞争风险回归多变量分析,与 LT 后新发恶性肿瘤相关的显著风险因素为:受者年龄(亚分布风险比(SHR)=1.03,95%CI 1.03-1.04)、男性(SHR=1.45,95%CI 1.27-1.67)、非活体供者(SHR=1.67,95%CI 1.14-2.38)、首次 LT(SHR=1.35,95%CI 1.09-1.69)和初始肝脏疾病类型(酒精相关性肝病(SHR=1.63,95%CI 1.22-2.17)、原发性硬化性胆管炎(SHR=1.98,95%CI 1.34-2.91)和原发性肝肿瘤(SHR=1.88,95%CI 1.41-2.54))。初始免疫抑制方案无显著影响。
本研究证实,LT 受者特征与新发恶性肿瘤风险相关,这突显了为提高生存率而进行个体化筛查的必要性。